Sotoracib (AMG510): a new anti-cancer drug developed by the American company Amgen

The anti-cancer drug sotoraxib (AMG510) originated from the in-depth research and development of the American company Amgen. The drug, also known as sotorasib, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) confirmed by specific testing to carry the KRAS G12C mutation and who have received at least one prior systemic therapy.

Amgen's clinical development program for sotoraxib is designed to fully exploit the properties of the KRAS G12C mutation to address the long-standing unmet treatment needs of patients with this type of cancer. Sotorasiib is not only the first KRAS G12C inhibitor to enter clinical trials, but is currently being explored in multiple combination therapies in the largest clinical research projects. This once-daily oral drug has demonstrated rapid, profound and durable anti-tumor activity in patients with non-small cell lung cancer carrying the KRAS G12C mutation, with a positive efficacy-to-risk ratio. In addition, studies of sotoracib in a variety of other solid tumors are also in progress.

Mutations in the KRAS gene lead to the production of an abnormal protein, which triggers the uncontrolled growth of cancer cells. The active ingredient sotorasib can accurately attach to the abnormal proteins in these cancer cells. This attachment not only blocks the function of abnormal proteins and cuts off the chemical signals that cancer cells rely on for growth and spread, but also promotes the death process of cancer cells. Although sotoracib has shown significant efficacy during treatment, patients should also be aware of its possible side effects, such as diarrhea, nausea, and fatigue.